Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I

被引:127
|
作者
Bonaca, Marc [1 ]
Scirica, Benjamin
Sabatine, Marc
Dalby, Anthony [3 ]
Spinar, Jindrich [4 ]
Murphy, Sabina A.
Jarolim, Peter [2 ]
Braunwald, Eugene
Morrow, David A.
机构
[1] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] S African Cardiol Clin Trials Grp, Johannesburg, South Africa
[4] Univ Hosp St Ann, Pekarska, Czech Republic
关键词
troponin; prognosis; sensitive; acute coronary syndrome; ACS; ACUTE CORONARY SYNDROMES; MYOCARDIAL-INFARCTION; EARLY-DIAGNOSIS; ELEVATION; MORTALITY; OUTCOMES; EVENTS; RISK;
D O I
10.1016/j.jacc.2010.01.044
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The purpose of this study was to investigate the prognostic implications of low-level increases in cardiac troponin I (cTnI) using a current-generation sensitive assay in patients with suspected acute coronary syndrome (ACS). Background Recent enhancements in troponin assays have enabled resolution of the 99th percentile reference limit at progressively lower concentrations. However, the clinical significance of low-level increases with sensitive assays is still debated. Methods We measured cTnI using a sensitive assay (TnI-Ultra, Siemens Healthcare Diagnostics, Deerfield, Illinois) at baseline in 4,513 patients with non-ST-segment elevation ACS randomly assigned to ranolazine or placebo. We applied decision limits at the 99th percentile reference limit (0.04 mu g/l), the cut point of the predecessor assay (0.1 mu g/l), and 1 equivalent to elevation of creatine kinase-myocardial band (1.5 ng/ml). Results Patients with baseline cTnI >= 0.04 mu g/l (n = 2,924) were at higher risk of death/myocardial infarction (MI) at 30 days than were patients with a negative cTnI (6.1% vs. 2.0%, p < 0.001). After adjusting for the TIMI (Thrombolysis In Myocardial Infarction) risk score, cTnI >= 0.04 mu g/l was associated with a 3-fold (95% confidence interval: 2.0 to 4.4, p < 0.001) higher risk of death/MI at 30 days. Moreover, patients with low-level increases (0.04 mu g/l to <0.1 mu g/l), were at significantly higher risk of death/MI at 30 days (5.0% vs. 2.0%, p = 0.001) and death at 12 months (6.4% vs. 2.4%, p = 0.005) than were patients with cTnI <0.04 mu g/l. Conclusions Low-level increases in cTnI using a sensitive assay identify patients at higher risk of death or MI. These findings support current American College of Cardiology/American Heart Association recommendations defining MI, and the incremental value of newer, more sensitive assays in identifying high-risk patients with ACS. (J Am Coll Cardiol 2010;55:2118-24) (C) 2010 by the American College of Cardiology Foundation
引用
收藏
页码:2118 / 2124
页数:7
相关论文
共 50 条
  • [41] A clinically sensitive cardiac troponin I assay (AccuTnI) versus the high sensitive cardiac troponin T assay to predict early serious cardiac outcomes in patients with potential acute coronary syndrome
    Kavsak, P.
    Worster, A.
    Devereaux, P.
    Heels-Ansdell, D.
    Guyatt, G. H.
    Opie, J.
    Mookadam, F.
    Hill, S.
    CLINICAL BIOCHEMISTRY, 2011, 44 (13) : 1174 - 1174
  • [42] Determinants and prognostic significance of an intra-dialysis rise of cardiac troponin I measured by sensitive assay in hemodialysis patients
    Solmaz Assa
    Ron T. Gansevoort
    Ralf Westerhuis
    Anneke C. Muller Kobold
    Adriaan A. Voors
    Paul E. de Jong
    Stephan J. L. Bakker
    Casper F. M. Franssen
    Clinical Research in Cardiology, 2013, 102 : 439 - 445
  • [43] Determinants and prognostic significance of an intra-dialysis rise of cardiac troponin I measured by sensitive assay in hemodialysis patients
    Assa, Solmaz
    Gansevoort, Ron T.
    Westerhuis, Ralf
    Kobold, Anneke C. Muller
    Voors, Adriaan A.
    de Jong, Paul E.
    Bakker, Stephan J. L.
    Franssen, Casper F. M.
    CLINICAL RESEARCH IN CARDIOLOGY, 2013, 102 (06) : 439 - 445
  • [44] Evaluation of a sensitive rapid assay for cardiac troponin I (cTnI) as implemented on the ARCHITECT® ci8200 Analyzer
    Boyd, JC
    Henrich, LM
    Schubert, MJ
    Shumaker, NR
    CLINICAL CHEMISTRY, 2005, 51 : A19 - A19
  • [45] Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome
    Weber, Michael
    Bazzino, Oscar
    Navarro Estrada, Jose Luis
    de Miguel, Raul
    Salzberg, Simon
    Fuselli, Juan J.
    Liebetrau, Christoph
    Woelken, Mariella
    Moellmann, Helge
    Nef, Holger
    Hamm, Christian
    AMERICAN HEART JOURNAL, 2011, 162 (01) : 81 - 88
  • [46] Evaluation of the analytical and clinical performance of a new high-sensitivity cardiac troponin I assay: hs-cTnI (CLIA) assay
    Li, Ling
    Shu, Xin
    Zhang, Litao
    Xu, Ao
    Yang, Juan
    Jing, Yisha
    Wang, Hui
    Zhang, Zhenlu
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2024, 62 (02) : 353 - 360
  • [47] Evaluation of a high-sensitivity cardiac troponin I assay compared to a first-generation cardiac troponin I assay in Doberman Pinschers with and without dilated cardiomyopathy
    Klueser, Lena
    Maier, Elizabeth T.
    Wess, Gerhard
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2019, 33 (01) : 54 - 63
  • [49] FIRST EXPERIENCES WITH THE SENSITIVE TRIAGE(R) CARDIAC TROPONIN I ASSAY IN THE EMERGENCY SETTING
    Baum, H.
    Schmid, M.
    Haeussler, M.
    Schweiker, M.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S670 - S670
  • [50] Analytical and clinical performance evaluation of surelite 8 for high-sensitivity cardiac troponin I assay
    Yin, P.
    Miao, W.
    Yang, T.
    Yu, S.
    Lee, D.
    Dai, L.
    CLINICA CHIMICA ACTA, 2024, 558